A stochastic framework for evaluating CAR T cell therapy efficacy and variability.

Based on a deterministic and stochastic process hybrid model, we use white noises to account for patient variabilities in treatment outcomes, use a hyperparameter to represent patient heterogeneity in a cohort, and construct a stochastic model in terms of Ito stochastic differential equations for testing the efficacy of three different treatment protocols in CAR T cell therapy. The stochastic model has three ergodic invariant measures which correspond to three unstable equilibrium solutions of the deterministic system, while the ergodic invariant measures are attractors under some conditions for tumor growth. As the stable dynamics of the stochastic system reflects long-term outcomes of the therapy, the transient dynamics provide chances of cure in short-term. Two stopping times, the time to cure and time to progress, allow us to conduct numerical simulations with three different protocols of CAR T cell treatment through the transient dynamics of the stochastic model. The probability distributions of the time to cure and time to progress present outcome details of different protocols, which are significant for current clinical study of CAR T cell therapy. • A Stochastic model in terms of Ito stochastic differential equations for CAR T cell therapy is proposed. • The stochastic model has three ergodic invariant measures which correspond to three equilibrium solutions of the deterministic system. • Define two stopping times, the time to cure and time to progress, and design three different protocols of CAR T cell therapy. • Conduct in silicon clinical trials CAR T cell treatment through the transient dynamics of the stochastic model. • Probability distributions of the time to cure and time to progress present outcome details of different protocols. [ABSTRACT FROM AUTHOR]